Early Parkinson Disease
Key Points
Key Points
- The treatment options for the alleviation of motor symptoms in the early stages of Parkinson disease (PD) are based on the enhancement of dopaminergic tone with levodopa, monoamine oxidase inhibitors, dopamine agonists (DAs), or a combination thereof.
- The choice of initial treatment is influenced by the potential for neuropsychiatric adverse effects associated with DAs and dyskinesia and motor fluctuations associated with levodopa.
Treatment
...atment
.... DAs vs. MAO-B inhibitors...
...ld counsel patients with early PD on the bene...
...patients with early PD who seek treatment fo...
...y prescribe DAs as the initial dopaminergic...
...ns should not prescribe DAs to patients with early...
...ibing levodopa...
...ns should initially prescribe immediate-release...
...h early PD, clinicians should prescribe...
...ns should routinely monitor patients taking le...
...uld counsel patients taking levodopa that...
...hould counsel patients that in later dise...
...escribing D...
...s should inform the patient and caregiv...
...should screen patients for cogniti...
...ians should screen patients for the presenc...
...ans should involve caregivers in ass...
Clinicians may screen patients for th...
...icians should integrate patient pref...
...ians should prescribe the lowest dose of DA r...
...ing and Discontinuing DAs
...s should recommend tapering or discontinuat...
...st be discontinued due to adverse effects, clin...
...escribing MAO-B inhibi...
...ns should counsel patients with early PD o...
...may prescribe MAO-B inhibitors as the init...
...for Parkinson DiseaseHaving trouble viewing t...